[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ramathibodi Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":131},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,75,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100633970","snapdandcgmintype2diabetes-100633970",false,"NCT07533604","SnapDandCGMinType2Diabetes","The Effectiveness of an AI-powered Thai Food Analysis (SnapD) and Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes and Overweight or Obesity: A Randomized Controlled Pilot Study","SnapD in T2DM","Inclusion Criteria:\n\n1. Aged 18 to 65 years, male or female at birth\n2. Diagnosed with type 2 Diabetes Mellitus with overweight or obesity (BMI\\>23 kg\u002Fm²)\n3. Hemoglobin A1c (HbA1c) 6.5-9% measured within 3 months prior to the screening date\n4. Willing to maintain their current antidiabetic medication regimen without dose adjustment for the entire 8-week study duration\n5. Must possess an internet-enabled devices e.g. smartphone, tablet compatible with the SnapD application\n6. Able and willing to adhere intervention, including using snapD and CGM\n\nExclusion Criteria:\n\n1. Currently pregnant, plan pregnancy or breastfeeding during the 8-week study period\n2. Current participation in another interventional clinical trial\n3. Current use of insulin or incretin-based therapies (e.g., GLP-1 Receptor Agonists, GIP\u002FGLP-1 Receptor Agonists)\n4. Presence of severe hearing or visual impairment that, in the investigator's judgment, would preclude the participant from safely and effectively using the SnapD application or the CGM device\n5. known contraindication to CGM usage e.g., a history of severe hypersensitivity to the device's materials or adhesive, planing to go on CT-contrasted imaging etc.","ALL","18 Years","65 Years",{"count":21,"type":22},45,"ESTIMATED","INTERVENTIONAL",[25],"NA","Study Title: The Effectiveness of an AI-powered Thai food analysis (SnapD) and Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes and Overweight or Obesity: A Randomized Controlled Pilot Study Rationale: Effective dietary management is the cornerstone of treating Type 2 Diabetes (T2DM) and obesity. However, traditional manual food logging is often inaccurate and burdensome. While digital tools and Continuous Glucose Monitoring (CGM) have shown promise internationally, there is a lack of validated AI-powered tools specifically designed for Thai cuisine. This study introduces SnapD, an AI-powered platform (utilizing Gemini 2.5 Flash) designed to recognize Thai food, estimate nutritional values, and integrate with CGM data to provide personalized feedback.\n\nThe primary goal of this pilot study is to evaluate the efficacy of the SnapD application, both as a standalone tool and in combination with CGM, compared to Standard of Care in improving glycemic control (HbA1c) over 8 weeks. Additionally, the study aims to assess the feasibility, participant adherence, and safety of these digital interventions to inform a future, fully powered randomized controlled trial.\n\nStudy Design: This is an 8-week, randomized, open-label, parallel-group, superiority pilot study with a 1:1:1 allocation ratio. A total of 45 participants will be enrolled and assigned to one of three arms:\n\n1. Intervention Arm 1: SnapD application + Real-time CGM + Diabetes Self-Management Education and Support (DSMES)\n2. Intervention Arm 2: SnapD application standalone + DSMES\n3. Control Arm: DSMES alone Inclusion Criteria Highlights: Adults (18-65 years) diagnosed with T2D with BMI \\> 23 kg\u002Fm² (overweight\u002Fobesity) with HbA1c between 6.5% and 9.0% with Must possess a compatible smartphone\u002Ftablet Procedures: Baseline (Visit 1): All participants receive 20-30 minutes of DSMES. Intervention groups receive training on SnapD. Arm 1 receives a 15-day CGM sensor.During Study: Intervention arms log meals via SnapD (at least twice daily). Nutritionists conduct bi-weekly follow-up calls to address technical issues and provide support.\n\nEnd-of-Study (Week 8): Assessment of HbA1c, body weight, waist circumference, lipid profile, and patient-reported outcomes (self-care activities and user satisfaction) Primary Outcome: Mean change in HbA1c from baseline to 8 weeks Secondary Outcomes: Changes in Fasting Plasma Glucose (FPG), body weight, waist circumference, and lipid profiles, Diabetes self-management scores (SDSCA questionnaire), User satisfaction with the SnapD application, Incidence of adverse events (hypoglycemia\u002Fhyperglycemia).\n\nSignificance: This study will provide preliminary evidence on the synergistic benefits of AI-driven nutritional feedback and CGM in a Thai-specific context, supporting the development of scalable, culturally adapted digital health technologies for diabetes management.",[28],"Type2 Diabetes Mellitus",[30,31,32,33],"AI-powered Thai food analysis","Continuous Glucose Monitoring","Glycemic Control","Obesity","RECRUITING","2026-04-09",{"date":37,"type":38},"2026-04-16","ACTUAL",{"date":40,"type":38},"2026-01-20",{"date":42,"type":22},"2026-09-01",{"name":44,"class":45},"Ramathibodi Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":46},"100622003","wearable-device-to-promote-cpap-adherence-in-obstructive-sleep-apnea-osa-patients-100622003","NCT07377968","Wearable Device to Promote CPAP Adherence in Obstructive Sleep Apnea (OSA) Patients","Efficacy of Wearable Device to Promote CPAP Adherence in Patients With Obstructive Sleep Apnea (OSA); A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients (≥ 19 yr of age) with moderate to severe OSA (AHI ≥ 15 events\u002Fhr at the sleep clinic in Ramathibodi hospital\n* Study after EC approval to March, 2026\n* Patients with OSA who are prescribed CPAP therapy and accepted a trial of therapy\n\nExclusion Criteria:\n\n* Patients deny to provide an informed consent\n* Patients had active cardiovascular, pulmonary, psychiatric disease, and epilepsy\n* Patients had been previously used CPAP for treatment of OSA\n* Patients have a problem to use a wearable device or watch\n* Patients had used any smartwatch before\n* Patients do not have a smart phone","19 Years",{"count":56,"type":22},80,[25],"The goal of this study type: clinical trial is to evaluate adherence for CPAP used with wearable device in OSA patients comparing with controlled group; could include any of the following: adult patients (≥ 19 yr of age) with moderate to severe OSA (AHI ≥ 15 events\u002Fhr by polysomnography (PSG), according to the American Academy of Sleep Medicine, diagnosed at the sleep clinic in Ramathibodi hospital, patients with OSA who are first time to prescribed CPAP treatment and in the waiting process for their machine. The main question it aims to answer is: Could a wearable device help increase the adherence of CPAP in obstructive sleep apnea patients?\n\nPrimary outcome is adherence for CPAP: time usage per day(min) and % usage \\> 4 hours\n\nSecondary outcome are access sleepiness and quality of sleep by questionnaire (ESS and PSQI) in Thai version, the correlation between wearable-derived and CPAP data: Total sleep time(min), sleep stage (light, deep and REM), and health information: heart rate, oxygen saturation, stress, sleep score and step counting\n\nIf there is a comparison group: Researchers will compare wearable group and control group to see the effect of wearable to increase adherence of CPAP used.\n\nParticipants will\n\n* Divide into two group by randomization using 4 block randomization\n* In wearable group, the participants will receive wearable and download application, they allow to access all the time\n* In control group, the participants will receive wearable and download application, but they will not allow to access until they come to hospital for follow up at the end of the study",[60],"Obstructive Sleep Apnea (OSA)",[62,63,64,65],"adherence","OSA","wearable device","health","NOT_YET_RECRUITING","2026-01-22",{"date":69,"type":38},"2026-01-30",{"date":71,"type":22},"2026-01-06",{"date":73,"type":22},"2026-06-30",{"name":44,"class":45},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":46},"100591704","phase-1-the-effect-of-local-infiltration-of-tranexamic-acid-on-postoperative-blood-loss-in-orthognathic-surgery-100591704","NCT06983886","The Effect of Local Infiltration of Tranexamic Acid on Postoperative Blood Loss in Orthognathic Surgery","The Effect of Local Infiltration of Tranexamic Acid on Postoperative Blood Loss in Orthognathic Surgery : A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 18-50 years\n* undergoing orthognathic surgery (Bilateral sagittal split ramus osteotomies (BSSRO), with or without Le Fort I maxillary osteotomy)\n* ASA physical status I-II\n\nExclusion Criteria:\n\n* Genioplasty in the operation\n* History of allergy to tranexamic acid\n* History of thromboembolic disorders\n* Use of medications affecting blood coagulation (antiplatelet or anticoagulants) within the past 2 weeks\n* History of cerebrovascular disease\n* Pregnant or breastfeeding women","50 Years",{"count":84,"type":22},25,[86,87],"PHASE1","PHASE2","The effect of local infiltration of tranexamic acid in orthognathic surgery remains unclear. This study was conducted to evaluate the difference in postoperative blood loss, measured by surgical drain output, following orthognathic surgery. The investigation involved a within-subject comparison, where each side of the mandible received a different local anesthetic solution: one side was infiltrated with a mixture of lidocaine with adrenaline and tranexamic acid, while the other side received lidocaine with adrenaline and normal saline.",[90],"Postoperative Blood Loss in Patient Undergoing Orthognathic Surgery",[92,93,94,95,96,97],"Postoperative blood loss","Orthognathic surgery","Bilateral sagittal split ramus osteotomies","BSSO","BSSRO","Tranexamic acid","2025-05-14",{"date":100,"type":38},"2025-05-21",{"date":102,"type":22},"2025-05-12",{"date":104,"type":22},"2026-09-30",{"name":44,"class":45},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":121,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":4},"100550939","efficacy-of-platelet-rich-plasma-injection-compare-with-corticosteroid-in-pes-anserinus-pain-syndrome-100550939","NCT06453603","Efficacy of Platelet-rich Plasma Injection Compare With Corticosteroid in Pes Anserinus Pain Syndrome","Efficacy of Platelet-rich Plasma Injection Compare With Corticosteroid in Pes Anserinus Pain Syndrome, Randomized Controlled Trial Study","Inclusion Criteria\n\n* Over 18 years old\n* Patients diagnosed with Pes Anserine Pain Syndrome\n* Patients willing to participate in the research project by signing a consent form\n\nExclusion Criteria:\n\n* Patients with a localized knee infection or a disseminated infection within the past 3 months\n* Patients with thyroid disorders, rheumatoid arthritis, or other types of knee arthritis\n* Patients with abnormal blood coagulation or thrombocytopenia\n* Patients who are pregnant\n* Patients with any type of cancer\n* Patients who cannot follow up with treatment until the end of the project\n* Patients who are unwilling to participate in the project or wish to withdraw from the research project",{"count":114,"type":22},24,[25],"The goal of this research is to study the efficacy of treatment between PRP injection and corticosteroid injection in patients with pes anserinus bursitis. The research question is whether PRP can reduce pain more effectively than corticosteroids.\n\nThe study is divided into two groups: one group receiving PRP injections and the second group receiving corticosteroid injections. Treatment outcomes will be monitored at four time points: baseline, 4 weeks, 12 weeks, and 24 weeks. The outcomes will be measured using the VAS and WOMAC scores.",[118,119,120],"Pes Anserine Bursitis","Steroid Injection","PRP Injection",[118,119,122],"PRP injection","2024-06-10",{"date":125,"type":38},"2024-06-11",{"date":127,"type":22},"2024-07-01",{"date":129,"type":22},"2026-12-31",{"name":44,"class":45},""]